Cancer type
By grouping the studies into four predefined diagnostic groups
(hematologic malignancies, central nervous system tumors, solid tumors
and mixed), we analyzed SPR related to cancer diagnosis (Figure 3). We
included 16 cohorts of survivors with hematological malignancies (n=7),
CNS tumors (n=4), solid tumors (n=2), and mixed diagnosis (n=3). The
studies of mixed diagnosis were quite heterogenous. No statistically
significant difference in SPR in regard to diagnosis was found (p=0.33),
although we found a tendency to a higher participation in late effect
studies of solid tumors compared to hematologic malignancies.